Articles related to OCULAR SURFACE

Understanding the ocular side effects of targeted cancer therapies is crucial. Early monitoring and interdisciplinary communication can significantly impact treatment outcomes.

For a comprehensive approach to refractive IOL surgery, understanding the nuances of preoperative assessment and ocular surface optimization is essential. Dive deeper into effective protocols to ensure optimal patient outcomes.

Explore the latest insights into corneoscleral topography to enhance your scleral lens fitting process. Advanced imaging techniques and a new classification system offer valuable guidance.

This article provides a comprehensive overview of the role of scleral lenses in managing ocular surface disease, highlighting the importance of understanding the ocular surface, scleral shapes, and the impact of systemic diseases. It offers valuable insights into the complexities of fitting scleral lenses and managing OSD.

Aldeyra’s reproxalap shows considerable promise as a breakthrough treatment for ocular surface inflammatory conditions, highlighting its potential in addressing a significant unmet need in the field of optometry. Explore these groundbreaking clinical trial results.

Unveiling fresh perspectives on dry eye disease treatment through a comprehensive study that scrutinizes tear proteomic analysis and clinical parameters. In a breakthrough study on dry eye disease (DED) treatment, researchers employed tear proteomic analysis to identify potential tear biomarkers. They combined this with a rigorous examination of clinical parameters. Data was gathered from a double-blinded, national multicenter clinical trial involving 80 DED patients. The subjects underwent treatment with either 0.1% cyclosporine, 0.05% cyclosporine, or 3% diquafosol eye drops. Observations took place at four-week intervals, lasting for 12 weeks. Key metrics observed included tear break-up time, corneal erosion, conjunctival erosion, and symptom assessment in dry eye scores. This data was then correlated with protein expressions identified through the proteomic analysis. Interestingly, the same seven proteins were identified in all treatment groups. These proteins were noted to be downregulated following treatment. At the 12-week mark, all clinical parameters demonstrated a significant improvement from the baseline. However, among the groups, no significant differences in values were recorded, except in the case of corneal erosion. The latter parameter significantly improved after treatment with both cyclosporine concentrations, as compared to the diquafosol group. However, the correlation of these proteins with the clinical parameters was […]